GlassScriptPhysician profile
Rajendra A Patel
NPI 1831191105
$9,020.26
in general payments reported to CMS, 2019-2025
45 companies · $1,463 in 2025
The $1,463 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,462 · 2020: $1,180 · 2021: $568 · 2022: $1,271 · 2023: $1,428 · 2024: $1,649 · 2025: $1,463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,498 · Education: $41.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,497.68 |
| Education | $41.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,395.79 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $1,138.74 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $785.48 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Daiichi Sankyo INC. | $706.14 | 2019-2024 | Injectafer |
| Pfizer INC. | $701.47 | 2019-2025 | |
| Novo Nordisk INC | $625.13 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $614.43 | 2019-2025 | Xifaxan |
| Abbvie INC. | $467.66 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $385.69 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Lilly USA, LLC | $314.04 | 2020-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $267.99 | 2020-2023 | |
| Sanofi-Aventis U.S. LLC | $201.71 | 2019-2023 | |
| Exact Sciences Corporation | $140.66 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $133.39 | 2019-2021 | |
| Astellas Pharma US INC | $112.89 | 2019-2023 | Veozah |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajendra Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.